Affymetrix's Q4 Revenues Shrink 4 Percent on Weaker Product Sales

Affymetrix President and CEO Kevin King said that the overall decline in its business was driven by a "major slowdown in scientific services and lower-than-expected sales within the discovery segment of our business."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories